Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have found that patients with chronic ongoing headaches can be treated effectively. The judicious use of an appropriate prophylactic medication combined with counseling, biofeedback and relaxation therapy, physical therapy, and/or stress management can result in the amelioration of the problem in many headache sufferers.
Int J Dermatol 1987 Sep
PMID:Headaches. Evaluation and therapy. 365 44

Three heroin addicts had Candida folliculitis of the scalp, beard, and pubis associated with fever, chills, headache, and fatigue. In each case, pseudohyphae were found within a hair and yeasts around it and Candida was recovered from urine. These facts support a systemic dissemination. Since serious ocular and osteoarticular lesions have been described with this type of skin lesion, prompt diagnosis may be important to initiate treatment and prevent sequelae.
Int J Dermatol 1986 Mar
PMID:Candida folliculitis in heroin addicts. 369 50

We have treated 48 cases of onychomycosis (of which 37 were caused by dermatophytes, 10 by yeasts and one by Scopulariopsis brevicaulis) with 200 mg ketoconazole daily. We obtained recovery in 65 p. 100 of the cases of onyxis caused by dermatophytes and in 80 p. 100 of the cases of onychomycosis due to Candida. The one patient presenting an infection with Scopulariopsis brevicaulis recovered in 13 months. The average duration necessary to obtain complete recovery was 6 1/2 months for onychomycosis of the hands due to dermatophytes and 12 1/2 months for those of the feet. Perionyxis due to Candida needed 2 months of treatment with this drug, however 6 months of treatment were necessary to obtain recovery for onycholysis due to Candida. Biological tests remained normal and the side-effects were minimal and essentially gastrointestinal in our study. Ketoconazole is an effective treatment for onychomycosis: it is active against the different mycotic agents infecting nails and well tolerated by the patient. Several minor effects such as itching, nausea, headache and more serious reactions such as erythrodermia and hepatitis have been reported. Regular control and biological tests are therefore necessary. Patients with other diseases should avoid the use of ketoconazole for treatment of onychomycosis.
Ann Dermatol Venereol 1984
PMID:[Ketoconazole and onychomycosis]. 608 41

Host defense against viral infection is extremely complex and includes both humoral and cellular immune mechanisms. This contribution examines the mechanisms by which antibody (Ab) and the complement (C) system, major constituents of the humoral immune system, inactivate viruses and block viral maturation in virus-infected cells in vitro. Ab and C may neutralize viruses by envelopment in a coating of protein, by aggregation by lysis, or by facilitating interactions with various effector cells. Ab and C molecules deposited on the surfaces of viruses may physically interfere with the ability of the virus to infect a potentially susceptible cell. This appears to be the most common mechanism by which Ab and C neutralize viruses. In rare instances, Ab and/or C may aggregate viruses; aggregation reduces the net number of infectious particles and thus is manifest as neutralization. C may lyse enveloped viruses, resulting in irreversible viral inactivation. However, this does not appear to be a major mechanism of viral neutralization. Finally, the Fc portions of bound Ab molecules as well as bound C molecules may interact with effector cells with specific receptors for these factors and thereby facilitate viral destruction. In regard to virus-infected cells, the deposition of Ab or C on the cell surface may prevent the maturation or release of viral particles and alter normal cellular functions. Ab and C may also lyse virus-infected cells, abruptly stopping further viral maturation. Such lytic events require only the F(ab')2 portion of the Ab molecule and proceed via activation of the alternative C pathway. Effector cells may also interact with Ab and/or C molecules deposited on virus-infected cells, leading to cytotoxic reactions and/or ingestion depending on the type of effector cell involved. The activated C system has the ability to produce an acute inflammatory response leading to alterations in vessel permeability, edema, changes in smooth-muscle contractility, and the influx of leukocytes. Such inflammatory responses occurring in tissues, including the skin, as a result of C activation not only retard the spread of the infection and facilitate the destruction of the infectious agent, but also in all likelihood damage normal tissues in the vicinity. In addition, C activation in tissues also has the ability to stimulate arachidonic acid metabolism and induce the release of histamine and other mediators as well as pyrogens from appropriate cell types. A number of the systemic symptoms characteristic of viral infections, such as headaches, myalgias, and fever, likely result from such processes.
J Invest Dermatol 1984 Jul
PMID:The role of antibody and complement in the control of viral infections. 637 46

Three patients with Darier's disease were treated with 1 X 10(6) IU of orally administered vitamin A daily for 14 days. In all patients, 50% to 80% improvement in the skin lesions was noted. Desquamation was minimal, and side effects consisted of drowsiness, mild frontal headache, dry lips and dry nose. During therapy, all patients had a transient, mild increase in the serum triglyceride level, and two patients had a minimal increase in the serum cholesterol concentration.
Arch Dermatol 1982 Nov
PMID:High-dose vitamin A therapy for Darier's disease. 713 44

Etiocholanolone is a physiologically occurring metabolite of testosterone and androstenedione which are secreted by adrenals, testes, and ovaries. Free, unconjugated etiocholanolone is formed in the liver and is found in the blood in very low concentrations. Usually, cases of etiocholanolone fever can be associated with symptoms such as elevated ESR, leukocytosis, myalgia, arthralgia, abdominal pain, diarrhea, and vomiting. In the case discussed in this paper a 17 year old girl had been suffering from headaches, vomiting, and fever during the 1st days of menstrual bleeding for several years accompanied by a supervening generalized urticarial eruption lasting for 3-5 days. The patient's mother was found to have elevated levels of unconjugated etiocholanolone in her blood which raised the possibility of a genetically determined defect in the conjugation of this steroid in the liver. The parallel appearance of skin eruptions and the febrile attacks leads to the interpretation that both events are triggered by the increase of the unconjugated etiocholanolone before and during menstruation. With high-dose glucocortisteriod therapy (100 mg prednisolone daily) the fever and rash could be suppressed within several hours of administration. In addition, with the administration of oral contraceptives Ovoresta M and later Lyndiol only one relapse was noted during 18 months.
Br J Dermatol 1981 Jul
PMID:Urticaria in association with etiocholanolone fever. 725 75

We have previously shown that cimetidine, given concurrently for 2 weeks to patients on chronic dapsone therapy, reduced methaemoglobinaemia by inhibiting the formation of the toxic hydroxylamine metabolite of dapsone. The aim of the present study was to examine the effect of this combination on the benefit/toxic ratio of dapsone over a longer period. Eight patients (six dermatitis herpetiformis, one linear IgA disease, one folliculitis decalvans) on long-term dapsone 50-100 mg daily, took cimetidine 1.6 g daily concurrently for 3 months. At 3-weekly intervals, a clinical assessment was made, plasma dapsone and methaemoglobin were measured, and parameters of oxidative haemolysis were monitored. The dapsone level rose from 2298 +/- 849 ng/ml (mean +/- SD) at baseline to 3006 +/- 1131 ng/ml at week 3 of cimetidine (P < 0.01). This rise in plasma dapsone was sustained during cimetidine administration, falling to 2446 +/- 954 ng/ml when cimetidine was stopped (P < 0.02). The methaemoglobin fell from 5.5 +/- 2.2% (mean +/- SD) at baseline to 3.9 +/- 1.1% at week 3 (P < 0.01), and remained low until week 12, when there was a return to baseline values (P < 0.01). The haemoglobin did not change from the baseline of 12.7 +/- 0.3 g/dl (mean +/- SD), and other parameters of haemolysis were unaltered. There was a fall in the visual analogue score for headache (P < 0.05), but this was not associated with any deterioration in control of the skin disorders. Hence, long-term concurrent cimetidine results in increased plasma dapsone levels without increased haemolysis, and is accompanied by reduced methaemoglobinaemia for more than 2 months.(ABSTRACT TRUNCATED AT 250 WORDS)
Br J Dermatol 1995 Feb
PMID:Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. 788 63

Since 1974, phototherapy with psoralen and ultraviolet A (UVA) has been used successfully for the treatment of psoriasis. However, undesirable side effects, including phototoxicity, nausea, stomach pain and headaches, have led investigators to develop new psoralen compounds. 5-Methoxypsoralen (5-MOP) has thus been introduced as an alternative to 8-MOP because of its less pronounced side effects. Since the absorption kinetics and bioactivity of 5-MOP are known to be variable, a new micronized tablet form (5-MOPm) has been developed. In an open randomized study, oral treatments with 5-MOP or 5-MOPm plus UVA radiation were compared in 22 psoriatic patients. Skin type and initial psoriasis area severity index did not differ significantly between treatment groups. Serum concentrations were significantly higher (320 vs 85.82 ng/ml) and occurred earlier (51.8 vs 229.09 min) with 5-MOPm. In addition, a reduction in PASI of more than 90% was achieved sooner (10.63 vs 17.27 treatments) and with a lower cumulative UVA dose (145.89 vs 232.11 J/cm2), in the group treated with 5-MOPm. No side effects were observed with 5-MOPm. Our data indicate that 5-MOPm has a higher bioavailability, clinical efficacy and tolerability than the commonly used 5-MOP.
Arch Dermatol Res 1994
PMID:Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation. 814 9

A 46-year-old female had suffered from systemic lupus erythematosus (SLE) for 8 years. Headache, vomiting and stiff neck appeared in the active phase of SLE. Findings in the cerebrospinal fluid were consistent with those of lupus meningitis. No pathogenic microbes were detected by microbiological or immunological examinations. She was diagnosed as having lupus meningitis. The method discussed herein which elucidates the cause of fever in SLE using white blood cell count (WBC) and alpha-2 globulin appeared to be useful for examining this case of meningitis. Lupus meningitis seems to preferentially occur in SLE patients with positive anti-ribonucleoprotein (RNP) antibody. Pulse therapy with methylprednisolone appeared to work well in this lupus meningitis patient who had had a long course of corticosteroid therapy.
J Dermatol 1993 Sep
PMID:A case of lupus meningitis treated successfully with methylprednisolone pulse therapy. 822 13

The efficacy of cyclosporin A (CyA) treatment was studied in seven patients with chronic dermatitis of the hands. CyA was started at a daily dose of 2.5 mg/kg in five patients, and 1.25 mg/kg in two patients. In patients who responded to the treatment at 2.5 mg/kg/day, the daily CyA dose was reduced stepwise, to the lowest maintenance dose of 1.25 mg/kg. In patients who did not respond, the dose was increased, to a maximum of 5 mg/kg/day. The patients were treated for 2-16 weeks. In six of the seven patients the dermatitis responded to CyA treatment within a few weeks. No response was seen with a starting dose of 1.25 mg/kg/day. In three of the five patients with a starting dose of 2.5 mg/kg/day, the daily CyA dose could be reduced to 1.25-2 mg/kg/day. After stopping CyA treatment, the dermatitis recurred during follow-up in three patients, three remained in remission, and one patient was not available for study. Treatment-related side-effects occurred in three patients. CyA treatment had to be stopped in one patient due to headache. The present study suggests that CyA could be a useful treatment for chronic dermatitis of the hands not responding to conventional therapy.
Br J Dermatol 1994 Jan
PMID:Cyclosporin A in the treatment of chronic dermatitis of the hands. 830 21


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>